Epristeride

CAS: 119169-78-7
Molecular Formula: C25H37NO3
Molecular Weight: 399.56618
Product description:Product is a selective and non-competitive steroid Ⅱ type 5 a - reductase inhibitors, used in the treatment of benign prostatic hyperplasia and its mechanism of action is by inhibiting the conversion of testosterone to DHT and reduce the content of dihydrotestosterone within the prostate gland, lead to hyperplasia of prostate glands atrophy.Clinical pharmacokinetic a second chamber model, it absorbs quickly, in the digestive tract will be able to detect 0.25 hours after dosing drugs exist in serum, blood concentrations of peak 3 ~ 4 hours, phase elimination half-life (t1/2 beta) for 7.5 hours. Continuous dosing (5 mg/time, 2 times a day) on the sixth day, blood drug concentration can reach steady state. Renal excretion through gastrointestinal tract drainage, mainly by the few. The average protein conjugation rate as high as 97%. Distribution capacity is approximately equal to 0.5 L/kg, and the amount of fluid in a human body.